Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective factors and critical mucosal thickness for the stability of the peri-implant soft tissue margin over 5 years: A longitudinal cohort study.

Journal of periodontology·2026
Same author

Humans homozygous for rare or common hypomorphic IL23R variants are prone to tuberculosis.

The Journal of experimental medicine·2026
Same author

The Tunneled Coronally Advanced Flap (TCAF) for Root Coverage Procedures: Rationale, Indications, and a Novel Papilla-Based Decision Tree.

Journal of periodontal research·2026
Same author

Role of Toll-like receptors and oral-gut-brain axis in neurodegenerative and neuropsychiatric disorders.

Reviews in the neurosciences·2026
Same author

Current State and Future of Systemic Treatment for Elderly Patients With Head and Neck Cancer Undergoing Radiotherapy.

Head & neck·2026
Same author

DNA methylation in glioblastoma: insights from single-cell epigenomics.

Epigenomics·2026

Related Experiment Video

Updated: Jan 13, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

CD47/SIRPα Immune Checkpoint Modulation: A Synergistic Strategy for Next-Generation CAR Therapies.

Mohammad Javad Yousefi-Hashemabad1,2, Amirhossein Kamroo3,4,5, Ali Rezvanimehr5

  • 1Student Research Committee, Babol University of Medical Sciences, Babol, Iran.

Molecular Cancer Therapeutics
|January 10, 2026
PubMed
Summary

Chimeric antigen receptor (CAR) therapies show promise for cancer treatment but face challenges. Modulating the CD47/SIRPα axis may enhance CAR therapies by overcoming immune evasion, though safety concerns require further investigation.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.0K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.0K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR) therapies, including CAR T, CAR macrophages, and CAR-NK cells, have transformed cancer treatment.
  • CAR therapies face challenges like immune cell dysfunction, immunosuppressive tumor microenvironment, antigen heterogeneity, and toxicity.
  • The CD47/SIRPα axis is a key innate immune checkpoint regulating tumor cell clearance and immune cell cross-talk.

Purpose of the Study:

  • To explore the integration of CD47/SIRPα modulation with CAR-based immunotherapies.
  • To review pre-clinical and clinical advancements, safety considerations, and future directions for this combined approach.

Main Methods:

  • This narrative review synthesizes existing literature on CD47/SIRPα modulation and CAR therapies.
  • Discussion includes pre-clinical and clinical data, focusing on immune cell function, tumor microenvironment, and safety.

Main Results:

  • CD47/SIRPα immune-modulation can enhance CAR therapy by boosting immune cell infiltration, persistence, and phagocytic activity.
  • Blockade of CD47/SIRPα may lead to hematologic toxicities, CAR T cell clearance, and compensatory immune escape pathways.

Conclusions:

  • Integrating CD47/SIRPα modulation with CAR therapies offers a promising strategy to overcome immune evasion and enhance anti-tumor responses.
  • Future research should focus on selective targeting, combinatorial strategies, and novel CAR designs to optimize safety and efficacy for durable responses.